LBRX · Lb Pharmaceuticals Inc
$39.23
-1.77 (-4.32%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$1.32B
Shares
32.26M
Volume · Oct 21
247.14K
Avg daily vol (3M)
390.85K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.23
Open$41.10
Day$39.04–41.24
52W close$14.61–49.48
Avg vol 30d423K
Short int6.0M · 18.6% float · 14.5d
Short vol82%
DataSep 2025–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$85.69M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
1.8
Trailing earnings · reciprocal yield 55.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$327.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8,299.3%
Year over year · more shares
Price change (1Y)
+156.3%
Trailing year
Short interest
18.6%
Latest settlement · 14.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
−8%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
71%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+24%
trailing
YTD return
+76%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $42 › 200d $32 — 50d above 200d
Institutional flow
Distributing
6 of 114 funds reported for Sep 30 · net -2.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.63% of float · ▲ +7.0% MoM · 14.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 1-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
+98%
Y/Y
Free cash flow
$-35.3M
Balance sheet
$250.2M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
71%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $42 › 200d $32 — 50d above 200d
Institutional flow
Distributing
6 of 114 funds reported for Sep 30 · net -2.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.63% of float · ▲ +7.0% MoM · 14.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $15
Now $39 · 71%
Range high $49
vs 200-day avg +23%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LBRX
this stock
Lb Pharmaceuticals Inc
|
$1.32B | +76.2% | — | — | 18.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LBRX | +15.4% | +0.1% | +23.7% | +2.2% | +76.2% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | +14.9% | -0.6% | +16.1% | +0.8% | +62.9% |